Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral

被引:44
作者
Badagliacca, Roberto [1 ]
Pezzuto, Beatrice [1 ]
Poscia, Roberto [1 ]
Mancone, Massimo [1 ]
Papa, Silvia [1 ]
Marcon, Serena [1 ]
Valli, Gabriele [2 ]
Sardella, Gennaro [1 ]
Ferrante, Fabio [1 ]
Iacoboni, Carlo [1 ]
Parola, Daniela [1 ]
Fedele, Francesco [1 ]
Vizza, Carmine Dario [1 ]
机构
[1] Univ Roma La Sapienza, Dept Cardiovasc & Resp Sci, Sch Med 1, Policlin Umberto 1, I-00161 Rome, Italy
[2] Univ Roma La Sapienza, Dept Clin Med, Policlin Umberto 1, I-00161 Rome, Italy
关键词
pulmonary arterial hypertension; prostanoids; epoprostenol; treprostinil; survival; INTRAVENOUS EPOPROSTENOL PROSTACYCLIN; LONG-TERM TREATMENT; ARTERIAL-HYPERTENSION; SUBCUTANEOUS TREPROSTINIL; SILDENAFIL CITRATE; 1ST-LINE BOSENTAN; SURVIVAL; EFFICACY; SITAXSENTAN; REGISTRY;
D O I
10.1016/j.healun.2011.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Oral drugs have made the treatment of pulmonary hypertension (PH) feasible in non-expert centers, which could delay patient access to prostanoid therapy. METHODS: Fifty-seven consecutive patients with precapillary PH received a prostanoid in our center. Data at prostanoid initiation included modality of center referral, medical history, New York Heart Association [NYHA] class, exercise capacity, echocardiographic parameters, and hemodynamics. RESULTS: Overall survival at 1, 2, and 3 years was 85%, 69%, 55%, respectively. Non-survivors had worse NYHA class III/IV (17/12) than survivors (27/1; p < 0.01) and exercise capacity on 6-minute-walk distance (254 +/- 114 vs 354 +/- 91 meters; p < 0.01). Non-survivors were more frequently referred on oral therapy (83% vs 36%; p < 0.01) and had a higher rate of urgent prostanoid treatment (69% vs 17%;p < 0.0001). Multivariate analysis (hazard ratio [95% confidence interval]) found the independent prognostic factors were urgent prostanoid therapy (2.0 [1.1-3.9]) and NYHA class (3.5 [1.5-8.2]). Survivors had a significant response to prostanoid, improving NYHA class from 2.8 +/- 0.4 to 2.3 +/- 0.5 (p = 0.002), 6-minute walk distance from 354 +/- 91 to 426 +/- 82 meters (p = 0.0001), and pulmonary hemodynamics (pulmonary artery pressure from 56 +/- 13 to 44 +/- 18 mm Hg [p < 0.05]; cardiac index from 2.0 +/- 1.2 to 3.1 +/- 1.2 liters/min/m(2) [p = 0.002], and pulmonary vascular resistance from 17 +/- 10 to 8 +/- 6 WU [p = 0.001]). CONCLUSIONS: Referral of patients on oral treatment to a tertiary PH center is delayed and significantly affects prognosis. J Heart Lung Transplant 2012;31:364-72 (C) 2012 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:364 / 372
页数:9
相关论文
共 28 条
[1]   Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil [J].
Barst, R. J. ;
Galie, N. ;
Naeije, R. ;
Simonneau, G. ;
Jeffs, R. ;
Arneson, C. ;
Rubin, L. J. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) :1195-1203
[2]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[3]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[4]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415
[5]   Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension [J].
Barst, Robyn J. ;
Gibbs, J. Simon R. ;
Ghofrani, Hossein A. ;
Hoeper, Marius M. ;
McLaughlin, Vallerie V. ;
Rubin, Lewis J. ;
Sitbon, Olivier ;
Tapson, Victor F. ;
Galie, Nazzareno .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) :S78-S84
[6]   Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension A 1-Year, Prospective, Open-Label Observation of Outcome and Survival [J].
Benza, Raymond L. ;
Barst, Robyn J. ;
Galie, Nazzareno ;
Frost, Adaani ;
Girgis, Reda E. ;
Highland, Kristin B. ;
Strange, Charlie ;
Black, Carol M. ;
Badesch, David B. ;
Rubin, Lewis ;
Fleming, Thomas R. ;
Naeije, Robert .
CHEST, 2008, 134 (04) :775-782
[7]   Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) [J].
Benza, Raymond L. ;
Miller, Dave P. ;
Gomberg-Maitland, Mardi ;
Frantz, Robert P. ;
Foreman, Aimee J. ;
Coffey, Christopher S. ;
Frost, Adaani ;
Barst, Robyn J. ;
Badesch, David B. ;
Elliott, C. Gregory ;
Liou, Theodore G. ;
McGoon, Michael D. .
CIRCULATION, 2010, 122 (02) :164-U138
[8]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[9]  
Galie N, 2002, NEW ENGL J MED, V353, P2148
[10]   Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 [J].
Galie, Nazzareno ;
Olschewski, Horst ;
Oudiz, Ronald J. ;
Torres, Fernando ;
Frost, Adaani ;
Ghofrani, Hossein A. ;
Badesch, David B. ;
McGoon, Michael D. ;
McLaughlin, Vallerie V. ;
Roecker, Ellen B. ;
Gerber, Michael J. ;
Dufton, Christopher ;
Wiens, Brian L. ;
Rubin, Lewis J. .
CIRCULATION, 2008, 117 (23) :3010-3019